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Prevention of Travelers' Diarrhea by Nonantibiotic Drugs
Robert Steffen, Rolf Heusser, and Herbert L. DuPont From the Institute for Social and Preventive Medicine,
University of Zurich, Zurich, Switzerland; and the University
of Texas Health Science Center at Houston, The Medical
School, Houston, Texas
Travelers have resorted to a variety of drugs for prevention of diarrhea. No beneficial
prophylactic effect has been confirmed for halogenated hydroxyquinolines, lactobacilli,
antimotility drugs, ethacridine, and various other agents. In contrast, bismuth subsalicy-
ate (BSS) in liquid form reduced the incidence of diarrhea in students from the United
States living in Mexico and in tablet form in volunteers challenged by enterotoxigenic
Escherichia coli. In tourists visiting various developing countries, a randomized, double-
blind study was conducted in which 390 persons received a total of 2.1 or 1.05g of BSS
daily or placebo in tablet form in two doses. BSS reduced the incidence of diarrhea by
41% in the high-dose group and by 35% in the low-dosegroup without causing important
adverse reactions.
Since the advent of mass travel to exotic tropical des-
tinations, travelers have resorted to a variety of drugs
for the prevention of travelers' diarrhea. In 1957Kean
[1] observed that of 1,265 residents of the United
States returning from Mexico, 35% had taken
prophylactic medication. According to the author,
this figure might have been a slight overestimate of
the incidence of prophylaxis. In our more recent sur-
veys, we have found that, depending on their desti-
nation, 10%-250,10 of European travelers take some
medication to prevent emporiatric enteritis. Despite
the fact that, at least in Europe, we have observed
a definite trend away from prophylaxis to therapy
by self-medication, the findings of these surveys in-
dicate that it is important to evaluate the effective-
ness of prophylaxis. Few data exist from which to
judge such trends in travelers from the United States,
but it is our impression that chemoprophylaxis is em-
ployed in nearly one-half of travelers to high-risk
areas. Of the various antidiarrheal agents used, many
have not been studied for prevention of travelers' di-
arrhea. We have limited our evaluation of nonan-
tibiotic drugs in prophylaxis of travelers' diarrhea
to six groups of agents.
Hydroxyquinolines
The first agents to be broadly used for prophylaxis
were halogenated hydroxyquinolines. They wereorig-
inally introduced in 1934for use in the treatment of
Please address requests for reprints to Dr. Robert Steffen, In-
stitute for Social and Preventive Medicine, University of Zurich,
Sumatrastrasse 30, CH-8006 Zurich, Switzerland.
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intestinal amebiasis. However, it was not until 1958
that their efficacy in the prophylaxis of travelers' di-
arrhea was evaluated. Kean [1] recruited students
from the United States and Canada during college
registration for study in Mexico (table 1). Unfortu-
nately, it was impossible to enroll all the study popu-
lation before or immediately on their arrival; enroll-
ment usually took place on the third day abroad.
Using a randomized, double-blind method, Kean
compared the efficacy of iodochlorhydroxyquin,
which is available commercially as Entero-Vioform
(dosage, 375 mg twice a day), with that of neomycin
and a placebo. Whereas neomycin was effective,
those who were taking iodochlorhydroxyquin showed
a slightly increased incidence of diarrhea as com-
pared with those who weretaking placebo. Similarly,
in the subgroup who started drug prophylaxis on the
first day abroad, the active agent did not reduce the
incidence of diarrhea. No adverse reactions were
reported.
In a second study, a Swedish group investigated
the efficacy of dibromoxyquinoline in Scandinavian
tourists who were vacationing in the Canary Islands
[2]. It is uncertain how the assignment of the tourists
to the drug groups was randomized. The active drug
was found to be distinctly superior to a placebo.
Again, not a single person complained about adverse
effects, which is surprising in view of the consider-
able frequency of such complaints obtained nowa-
days- even in placebo groups. Mentzing [3] then per-
formed a retrospective assessment of travelers who
had returned to Sweden. He demonstrated that those
who had taken one of a variety of hydroxyquino-
lines were more likely to have developed diarrhea,
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Table 1. Efficacy of nonantibiotic prophylaxis of travelers' diarrhea.
Design
Percentage
Type of agent, Random- No. of with Significance
study ized DB subjects diarrhea level Reference
Halogenated hydroxyquinolines
Iodochlorhydroxyquin + + 210 39 NSPlacebo 202 34
Dibromoxyquinoline NR + 114 9 P < .001 2Placebo 115 61
Various hydroxyquinolines * 256 40
Nothing 612 32 NO 3
Broxyquinolinbenzoxaldin 160 9 P < .01 4Nothing 160 54
Mexaforme 217 25 NO 5Nothing 300 13
Iodochlorhydroxyquint 499 3 P < .001 6,7Placebo" 279 15
Dichlorhydroxyquinoline NR + 230 10 P < .001 8Placebo 222 35
Lactobacilli
Lactobacilli + + 17 41 NS 9Placebo 14 14
Lactobacilli + + 23 70 NS 10Placebo 25 68
Lactobacilli + + 212t 55 NS 11Placebo 51
Ethacridine
Ethacridine NR 49 18 NS§
Placebo 49 35 12
Nothing 50 43 NS
Ethacridine + + 48 34 NS 13Placebo 149 38
Various chemoprophylactic agents
Furazolidone II NR NR 223 12 NOPlacebo II 113 42
Furazolidonef
14
NR NR 184 I NOPlacebo# 88 10
Phthalylsulfathiazole NR NR 168 12 P< .01 15Placebo 168 24
NOTE. DB = double-blind; NS = not significant; NR = not reported; and NO = not determined.
* Retrospective study.
t Twice a day, three times a day, and four times a day in three respective trials.
t The total number of subjects in the study.
§ P < .02 for the comparison of ethacridine vs. nothing.
II Once a day.
# Twice a day.
notably salmonellosis. It remains debatable whether
the treated and nontreated groups were drawn from
equivalent populations.
Other uncontrolled studies have looked at the ef-
fectiveness of iodochlorhydroxyquin in the preven-
tion of travelers' diarrhea [4-8] (table 1). Because
of the association of the drug with the syndrome of
subacute myelooptic neuropathy (SMON), which oc-
curs primarily in Japan [16] and rarely in other coun-
tries [17], use of this agent cannot be recommended.
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Lactobacilli
On the assumption that lactobacilli favorably mod-
ify the intestinal flora, the efficacy of the commer-
cial preparation Lactinexwas tested by two groups:
Pozo-Olano et al. [9], who conducted their trial in
travelers to Mexico, and Clements et al.[10], who
challenged volunteer college students with virulent
enterotoxigenic Escherichia coli (ETEC). Recently,
Kollaritsch et al. [11] distributed a similar dose of
Lactobacillus acidophilus to travelers. In each one
of the three studies it was concluded that ingestion
of lactobacilli did not reduce the incidence of
travelers' diarrhea.
Ethacridine
In the aforementioned pilot study [13], ethacridine,
a local antiseptic agent that was used by the Ger-
mans to treat diarrhea in World War II, was reas-
sessed. Richarz [12] claimed that it had a significant
beneficial effect in participants on a world cruise,
but he compared the treated group with untreated
travelers rather than with the placebo group. In our
pilot study, no reduction in the incidence of diar-
rhea was observed, and adverse reactions, mainly
nausea, were reported by 38% of those receiving
ethacridine, as compared with 230,10 of those in the
placebo group.
Antimotility Drugs
As Merson [18] has stated, diphenoxylate, which is
marketed as Lomotil, was used, and antimotility
agents are still used on occasion for prophylaxis of
emporiatric enteritis. However, the efficacy of di-
phenoxylate for this indication has not been tested.
In contrast, we have tested the efficacy of the ac-
tive metabolite of diphenoxylate, difenoxine [19], in
a controlled pilot study (figure 1).As previously de-
scribed [13], we evaluated the efficacy of six differ-
ent compounds among 653 tourists visiting Sri Lanka
or Kenya. Difenoxine was included in this trial only
because its distributor intended to promote its use
for prophylaxis of travelers' diarrhea. Difenoxine sig-
nificantly reduced the rate of well-being, partly by
an increase in the incidence of diarrhea and partly
by an increase in the rate of adverse reactions-
mainly constipation. We concluded that antimotil-
ity drugs are not to be recommended for prophylaxis
of travelers' diarrhea.
Other Chemotherapeutic Agents
In our study [13], which was conducted mainly to
exclude ineffective or even harmful agents from a
larger survey that is currently under way, we evalu-
ated various chemotherapeutic agents (figure 1).Nei-
ther sulfadoxine nor a preparation containing thiam-
phenicol, nitrafurantoin, and sulfafurazole, with the
trade name Fultrexin (Inpharzam, Cadempino, Swit-
zerland), significantly reduced the rate of diarrhea.
Only Streptotriad (May and Baker, Dagenham,
United Kingdom), which contains streptomycin and
three sulfonamides, which is discussed in more de-
tail in these proceedings by Sack [20], reduced the
rate of diarrhea and increased the rate of well-being
significantly.
More than 20 years ago, phthalylsulfathiazole [15]
and furazolidone [14] were reported to exert a
prophylactic effect without serious adverse effects,
but neither agent is widely used at the present time.
An additional preparation, trimethoprim-sulfameth-
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did not become ill, enteropathogens were detected
in approximately equal numbers in both treatment
groups. In contrast, in the patients with diarrhea,
an enteropathogen was identified in the stools of 71%
of the placebo-treated vs. 33% of the BSS-treated
students (P < .05). Gorbach [25], who has com-
mented that if travelers were to take BSS at the large
dose used in this study - 60 ml four times a day-
they would need to take an extra suitcase just for
their BSS bottles, concluded that this might provide
space with which to bring home souvenirs once the
drug was consumed. This dose had been arbitrarily
chosen in the study [22], and in the report we ac-
knowledged the need to determine the minimum pro-
tective dose.
Using volunteers who were challenged with ETEC
in a double-blind, placebo-controlled study, Graham
et al. [23] set out to determine this dose in a study
of the efficacy of the tablet form of BSS. Adminis-
tration of 600 mg of BSS in the form of two tablets
was begun 8 hr before challenge with ETEC and was
then continued 2 hr before challenge with ETEC and
2 hr and 4 hr after challenge and on a four-times-
daily regimen for three additional days. Volunteers
consumed a total daily dose of 2.4 g of BSS, which
was approximately one-half that used by DuPont et
al. in the earlier study [22]. Again, the drug not only
reduced to a significant extent the incidence of
diarrhea - the protection rate was 77% - but the two
subjects receiving BSS who had diarrhea were the
only ones who did not experience accompanying
symptoms such as nausea, vomiting, cramps, head-
9 11 ' 13 I 1'5 I 1'7 I 19 ' 2'1
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Figure 2. Plot-estimated probabilities of a subject re-
maining free of illness over 21 days of prophylaxis with
bismuth subsalicylate or placebo. The difference between
the two "survival" patterns, as assessed by the log-rank
method [24], was statistically significant (P < .001).
Reprinted with permission from lAMA [22].
Bismuth Subsalicylate (BSS)
Bismuth compounds were introduced to medicine
in the 18th century for the treatment of syphilis, yaws,
and various gastrointestinal disorders. In the 1920s
bismuth replaced mercury as the heavy metal of
choice for the intravenous treatment of syphilis un-
til its use started to decline with the discovery and
application of penicillin therapy. The value of bis-
muth salts in treating gastrointestinal disorders has
remained unconfirmed [21]. Controlled studies have
recently demonstrated that one bismuth salt, bismuth
subsalicylate, is effective in both treatment and pro-
phylaxis of travelers' diarrhea.
The initial studies that investigated BSS as a
prophylactic agent were carried out in 1977 among
students from the United States who were attending
summer classes in Guadalajara, Mexico [22]. The
volunteers who took the liquid form of the active
agent (4.2 g per day) experienced a lower incidence
of illness of both mild and moderate levelsof severity
(table 2). They also experienced fewer other intesti-
nal symptoms. The probabilities of the BSS and
placebo groups remaining free of diarrhea during
the 21-day study are illustrated in figure 2. The pro-
tection rate, which is defined as the reduction in in-
cidence of diarrhea between the drug and placebo
treatments and which is expressed as a percentage
such that 1000/0 indicates maximal protection, was
62%. The preparation was well tolerated; it is nota-
ble that the percentages of students with constipa-
tion (34% in the drug vs. 27% in the placebo group)
were not significantly different. Of the students who
oxazole, can be considered a nonantibiotic com-
pound for prophylaxis, but this agent will be dis-
cussed separately.
NOTE. Both studies were randomized and double-blind.
Table 2. Efficacy of bismuth subsalicylate (BSS) for
prevention of travelers' diarrhea.
Percentage
of subjects Signifi-
No. of with cance Ref-
Regimen subjects diarrhea level erence
BSS, 60 ml qid 62 23
(4.2 g per day) P < .0001 22
Placebo 66 61
BSS, 600 mg qid 15 13
(2.4 g per day) P< .03 23
Placebo 16 56
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ache, or fever. Further, ETEC were recovered from
the stools of only a fewof those receiving a placebo.
In addition, in one-half of those receiving BSS, an
antibody response to the organism's adhesion fim-
briae (CFA I) was demonstrated even in the absence
of the development of diarrhea.
To establish a minimal effective prophylactic dose
and to test the efficacy of a tablet formulation of
BSS in tourists - the population to whom it might
later be most frequently recommended - we recently
conducted a randomized, triple-blind study evalu-
ating BSS as prophylaxis of travelers' diarrhea
(authors' unpublished observations). Three treat-
ment regimens were tested: two 525-mg BSS tablets
taken twice daily, two 262.5-mg BSS tablets taken
twice daily, and a placebo. Subjects took the medi-
cation continuously from the day before departure
during the 12-28-day stay in the tropics, until the
second day after returning home. Three hundred ten
subjects were originally recruited for the study.
Twenty-six percent of the persons visitedKenya;23070,
West Africa; 13%, other parts of Africa; 23070, Asia
east of India; and 15070, South America. After the
exclusion of noncompliant subjects or subjects with
nonassessable cases, 231 volunteers could be included
in the evaluation of efficacy. The participants were
divided into two groups according to the degree of
compliance. Excellent compliance wasdefined as the
taking of all but six or fewer tablets of the medica-
tion. Fair compliance was defined as the missing of
no more than 20 doses.
For both the fair- and excellent-compliance sub-
groups, the incidence of diarrhea in both the high-
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and low-dosage groups was significantly reduced as
compared with that in the placebo group (table 3).
The high incidence of diarrhea in the placebo-group
as compared with the incidence found in our
epidemiologic studies [26] might primarily be ex-
plained by the fact that persons who are prone to
suffer from diarrhea were more likely to enroll in
the trial. The rates of protection against traveler's
diarrhea are shown in table 3. No differences in the
efficacy of BSS for travelers to different regions were
observed.
A comparison of our results with those of Gra-
ham et al. [23] indicates that the frequency of dos-
ing plays an important role in efficacy, since 2.4 g
of BSS given in four doses provided twice the pro-
tection of 2.1 g given in two doses.
In our study, overall adverse effects were reported
more frequently in both BSS-treated groups than in
the placebo group (P = .04). Constipation and nau-
sea were the principal complaints.
With respect to toxicity, it is important to note that
BSSiscomposed of approximately 60070 bismuth and
40% salicylate. It is hydrolyzed in the stomach to
bismuth oxychloride and salicylate.Over 90070 of the
salicylate is absorhed from the gastrointestinal tract
and excreted into the urine [27, 28]. In the first study
of BSS as prophylaxis [22], the amount of salicylate
in the liquid preparation administered to each sub-
ject corresponded to that in 8.3 325-mg aspirin
tablets per day, which is consistent with therapeutic
doses of aspirin. This daily dose of BSS would have
been equivalent to 3.3 aspirin tablets if the tablet for-
mulation had been used. Although it is not known
Table 3. Prophylactic efficacy of bismuth subsalicylate (BSS) in travelers' diarrhea.
Travelers' diarrhea
Type of
compliance, No. of Did not Incidence Significance Protection
daily regimen* subjects Developed develop (010) level rate (010)
Fair
2.1 g of BSS 88 38 50 43.2 P = .014 32.4
1.05 g of BSS 71 31 40 43.7 P = .024 31.6
Placebo 72 46 26 63.9
Total 231
Excellent
2.1 g of BSS 67 26 41 38.8 P = .007 40.6
1.05 g of BSS 54 23 31 42.6 P = .031 34.8
Placebo 52 34 18 65.4
Total 173
NOTE. Excellent compliance was defined as the taking of all but six or fewer tablets of BSS; fair, as the taking of all but
up to 20 tablets.
* All subjects were to take BSS twice a day.
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whether BSS cross-reacts with aspirin, patients with
a history of aspirin-associated allergy should refrain
from taking BSS-containing products. In addition,
care should be exercisedin the administration of BSS
to patients receiving anticoagulant therapy, persons
with gout, and persons taking probenecid, metho-
trexate, or other medications that contain aspi-
rin [29].
Between 1973and 1980, approximately 1,000cases
of bismuth-related encephalopathy were observed in
France [30, 31] and an additional 40 cases, in Aus-
tralia [32]. This adverse reaction has also been
reported in 12cases in four other countries [21]. Most
cases involved the ingestion of large quantities of bis-
muth subnitrate or bismuth subgallate (up to 20 g)
on a daily basis for as long as 30 years. None of the
patients had a levelof bismuth in blood of<100parts
per billion (ppb) [33]. Despite the fact that BSS was
introduced early this century, only one case of en-
cephalopathy due to BSShas been reported - in Aus-
tralia [34]. This occurred in a 60-year-old man who
had taken a BSS preparation for a number of years
in unknown doses for chronic diarrhea. In addition,
this subject was diabetic, had a history of chronic
ulcerative colitis, and had undergone surgery for pro-
tocolectomy, ileostomy, and splenectomy. No cases
of bismuth-induced encephalopathy due to BSS have
been reported in North America or have been as-
sociated with the use of Pepto-Bismol (Proctor &
Gamble, Cincinnati).
Hillemand et al. [35] have published a review on
the relationship of blood bismuth levels and enceph-
alopathy. They concluded that levels of >100 ppb
were toxic, levels of between 50 and 100 ppb were
considered an "alarm value," and levels of <50 ppb
were acceptable and should not produce signs of
bismuth-induced encephalopathy.
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All of the 10travelers whom westudied who volun-
teered to give a blood sample within five days after
the cessation of treatment had bismuth values that
did not exceed 10ppb. In the blood samples that had
been obtained in a previous study [22] from six sub-
jects within 24 hr of their discontinuation of daily
ingestion of 4.2 g of BSS for 21 days, all levels were
below the assay detection limit of 50 ppb [36].
In a study conducted by Procter & Gamble (un-
published data), 30 subjects were administered three
Pepto-Bismol tablets either four times a day (3.14
g of BSS per day) or twice a day (1.57g of BSS per
day) for six weeks. Blood samples were analyzed for
'bismuth before the start of treatment, at the end of
weeks 1, 2, 4, and 6 of treatment, and nine weeks
after cessation of treatment. The mean ± SD blood
bismuth levels of subjects taking 1.57 and 3.14 g of
BSS per day were 10.0 ± 6.6 and 15.0 ± 7.9 ppb,
respectively, at the end of six weeks of treatment.
Figure 3 shows the mean blood bismuth values ob-
served during this study in the four-times-a-day
group. The highest blood bismuth levelwas recorded
in an individual receiving the low dose at week 4 (34
ppb), None of the subjects showed any signs ofneu-
rotoxicity, and all blood bismuth levelsdecreased to
below the detection limit at nine weeks posttreat-
ment. Results of this study suggest that bismuth, un-
like salicylate, is poorly absorbed from the gastroin-
testinal tract. In addition, there is no evidence to
suggest that BSS, when taken by adults in reason-
able doses for up to three weeks for prophylaxis,
would result in bismuth-related encephalopathy.
Levine [37] has pointed out that Pepto-Bismol
tablets, unlike the liquid form, contain 350 mg of
calcium carbonate. Although most persons are able
to excrete excess calcium, it has been suggested that
prophylactic treatment with BSS tablets in some in-
Figure 3. Bioavailability of bismuth
after ingestion of 3.14g of bismuth sub-
salicylate per day in divided doses four
times daily. Reprinted with permission
from an unpublished study (IB-I01;
Proctor & Gamble, Cincinnati).
Week 15
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Figure 4. Dose-dependent inhibition of growth of en-
terotoxigenic Escherichia coli by bismuth subsalicylate.
Overnight cultures of ETEC weregrown in brain-heart in-
fusion broth (BHI). Growth in the presence of the com-
pounds was examined by inoculating 30 ml of BHI con-
taining the compound with 0.1 ml of a late log-phase
culture and incubating at 37°C on a rotating platform.
Abbreviations: LT = heat-labile; ST = heat-stable (en-
terotoxin properties). Figure is from [39].
tant strains in regions frequently visited by tourists
[43]. The data presented suggest that only one
nonantibiotic agent, BSS, be considered for prophy-
laxis. BSS has been repeatedly tested under con-
trolled conditions and appears to be safe and effec-
tive in the prevention of travelers' diarrhea. The
reported studies of BSS suggest that the dosage and
especially the number of daily doses are important.
One gram of BSS daily taken in two divided doses
appears to be the minimum efficacious dose, but a
protection rate in the range of 400/0 is not sufficient.
However, on the basis of the earlier studies [22, 23],
the traveler can be protected satisfactorily with a
slightly higher dose when the drug is taken more fre-
quently. Because of the convenience of the solid prep-
aration, we currently recommend it and suggest that
dividuals may produce a hypercalcemia via the milk-
alkali syndrome. The minimum amount of calcium
reported to produce this syndrome exceeds that con-
sumed in the recommended prophylactic dose. In ad-
dition, the Food and Drug Administration has con-
cluded in its review of over-the-counter antacid
ingredients that up to 8 g of calcium carbonate may
be consumed daily [38], a value in excess of any rea-
sonable prophylactic dose of BSS.
Recently, evidence has been put forward to sug-
gest a mechanism of action of BSS. The decreased
recovery of enteropathogens from the stools of pa-
tients given BSS in the earlier studies [22, 23] im-
plies that BSS may have bactericidal activity. Gra-
ham reported that the challenge strain that was used
in his study was sensitive to BSS. Further, Manhart
[39] demonstrated in vitro that BSS and, to a lesser
extent, bismuth oxychloride and salicylate, inhibited
growth of the most common enteropathogens at con-
centrations that are likely to be achieved in the up-
per small intestine (figure 4). Additionally, salicy-
lates have been shown to exhibit an antisecretory
effect by increasing net water absorption in intesti-
nal tissue after exposure to bacterial toxins [40, 41].
The reduced serologic response to infection in ex-
perimentally induced ETEC infection by pretreat-
ment with BSS suggests that the drug may interfere
with attachment of organisms to intestinal receptors.
Additionally, in a series of in vitro studies, the inhi-
bition by BSS of crude toxins of E. coli and Vibrio
cholerae was demonstrated [42]. It should be noted
that neither bismuth subcarbonate [36]nor bismuth
subnitrate [13] showed a significant prophylactic ef-
fect. Although there is evidence that a number of
factors may contribute to the overall efficacy of BSS,
precisely how and to what extent each of the com-
ponents contributes to the action of BSS remains
to be elucidated.
Conclusions
Three types of prophylaxis of travelers' diarrhea are
available to the traveler. The first approach, to take
no prophylaxis at all, is very reasonable, at least for
the majority of travelers to the developing world-
with the possible exceptions of the high-risk travelers
described previously and of those who have to ful-
fill important tasks during a brief stay abroad.
Prophylactic antibiotics are an alternative but cer-
tainly have the important disadvantages of poten-
tial serious adverse effects and induction of resis-
101
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it be administered in a dose of two tablets (262.5 mg
per tablet) three times a day (with meals) during the
period at risk for up to three weeks. This dosing
schedule represents an extrapolation from the studies
reported herein. The efficacy of this approach re-
mains to be investigated.
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